Orion Pharma partners with Qilu to commercialize pembrolizumab biosimilar in Europe

Bitget2026/10/06 06:00

Orion Pharma signed an agreement with Qilu Pharma Europe to commercialize an intravenous pembrolizumab biosimilar in Europe. Orion will hold exclusive rights to distribute, market, and sell the product across Europe. Qilu will supply the biosimilar, receive a profit share, and earn development, regulatory, and sales milestone payments. Qilu is currently developing the intravenous pembrolizumab biosimilar. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orion Oyj published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060200OMX_____CNEWS_EN_GNW1001276357_en) on October 06, 2026, and is solely responsible for the information contained therein.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Orion Pharma signed an agreement with Qilu Pharma Europe to commercialize an intravenous pembrolizumab biosimilar in Europe.
Orion will hold exclusive rights to distribute, market, and sell the product across Europe.
Qilu will supply the biosimilar, receive a profit share, and earn development, regulatory, and sales milestone payments.
Qilu is currently developing the intravenous pembrolizumab biosimilar.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orion Oyj published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060200OMX_____CNEWS_EN_GNW1001276357_en) on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.

华尔街见闻•2026/11/09 10:26